Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001795" target="_blank" >RIV/65269705:_____/12:#0001795 - isvavai.cz</a>
Result on the web
<a href="http://www.biomedcentral.com/1471-2407/12/415" target="_blank" >http://www.biomedcentral.com/1471-2407/12/415</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/1471-2407-12-415" target="_blank" >10.1186/1471-2407-12-415</a>
Alternative languages
Result language
angličtina
Original language name
Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma
Original language description
Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with relapsed and refractory multiple myeloma (R/R MM). In PX-171-003-A1, a single-arm phase 2 study of carfilzomib monotherapy in heavily pretreated patients, the overall response rate was 23.7%, 37% of patients achieved >= minimal response and median overall survival (OS) was 15.6 months. Based on this study, carfilzomib is under review by the US Food and Drug Administration for approval to treat R/R MM. Herein we describe the trial design and rationale for a phase 3 randomized study, FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study), being conducted to compare OS after treatment with single-agent carfilzomib to best supportive care(BSC) regimen in R/R MM.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BMC Cancer
ISSN
1471-2407
e-ISSN
—
Volume of the periodical
2012
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
415-422
UT code for WoS article
000311048500001
EID of the result in the Scopus database
—